Full Press Release Details
ADMA Biologics Announces Poster Presentation
RAMSEY, N.J. and BOCA RATON, FL., - October 3, 2019 -
ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"), a vertically integrated commercial biopharmaceutical
and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment
of immune deficiencies and the prevention of certain infectious diseases, announces that a poster presentation will be made at
IDWeek 2019, in Washington, D.C. This poster will detail the data obtained from the compassionate use of ASCENIV (formerly
referred to as RI-002) in the treatment of Respiratory Syncytial Virus ("RSV") infection in two immunocompromised children
at the Mayo Clinic, Rochester, MN.
Details of the poster presentation are below:
Title: Pediatric Respiratory Viral Infections
Session Date: Saturday October 5, 2019
Session Time: 12:15 PM - 1:30 PM
Session Location: Walter E. Washington Convention Center
Title: Treatment of RSV Lower Respiratory Tract Infection
in Two Immunocompromised Children with Polyclonal Immunoglobulin Containing Standardized Levels of Neutralizing Anti-RSV Antibody
and Poster Board Number: 2630
ADMA Biologics, Inc. (ADMA)
ADMA Biologics is a vertically integrated commercial biopharmaceutical company that manufactures and markets three United States
Food and Drug Administration ("FDA") approved plasma-derived biologics for the treatment of immune deficiencies and
the prevention of certain infectious diseases. ADMA's mission is to manufacture, market and develop plasma-derived, human
immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management
of immune compromised patient populations who suffer from an underlying immune deficiency disease, or who may be immune compromised
for other medical reasons. ADMA has received U.S. Patents 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to
certain aspects of its products and product candidates. For more information, please visit www.admabiologics.com.
About ASCENIV (Formerly referred to as RI-002)
ASCENIV , Immune Globulin Intravenous, Human - slra 10% Liquid, is a plasma-derived, polyclonal, intravenous immune
globulin ("IVIG"). ASCENIV is protected by U.S. Patents: 9,107,906, 9,714,283 and 9,815,886. ASCENIV
is manufactured using our unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends
normal source plasma and plasma from donors tested using our proprietary microneutralization assay. ASCENIV contains
naturally occurring polyclonal antibodies. ASCENIV is indicated for the treatment of Primary Humoral Immunodeficiency
or Primary Immune Deficiency Disease ("PI") in adults and adolescents (12 to 17 years of age). ADMA received
FDA approval for ASCENIV on April 1, 2019. Polyclonal antibodies are proteins that are used by the body's immune system
to neutralize microbes, such as bacteria and viruses and prevent against infection and disease. ASCENIV prevented
serious bacterial infection among 59 patients treated for twelve months during the pivotal investigation. The most common
adverse reactions to ASCENIV (>5% of study subjects) were headache, sinusitis, diarrhea, gastroenteritis viral,
nasopharyngitis, upper respiratory tract infection, bronchitis, and nausea. ADMA anticipates the commercial launch of ASCENIV
during the second half of 2019. Certain data and other information about ASCENIV or ADMA Biologics and its products
can be found on the Company's website at: www.admabiologics.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements"
pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. ("we",
"our" or the "Company"). Forward-looking statements include, without limitation, any statement that may
predict, forecast, indicate, or imply future results, performance or achievements, and may contain such words as "estimate,"
"project," "intend," "plan," "planning," "expect," "believe,"
"will," "is likely," "will likely," "should," "could," "would,"
"may," or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements
also include, but are not limited to, statements concerning our ability to operate in accordance with FDA quality and compliance,
regulations and expectations; our ability to successfully pursue commercialization and prelaunch activities for our products; and
the potential of our specialty plasma-based biologics products and product candidates to provide meaningful clinical improvement
for patients living with Primary Immune Deficiency Disease or other indications. Actual events or results may differ materially
from those described in this document due to a number of important factors. Except to the extent required by applicable laws or
rules, ADMA does not undertake any obligation to update any forward-looking statements or to announce revisions to any of the forward-looking
statements. Forward-looking statements are subject to many risks, uncertainties and other factors that could cause our actual results,
and the timing of certain events, to differ materially from any future results expressed or implied by the forward-looking statements,
including, but not limited to, the risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission,
including our most recent reports on Form 10-K, 10-Q and 8-K, and any amendments thereto.
Executive Vice President and Chief Financial Officer | 201-478-5552
INVESTOR RELATIONS CONTACT:
Managing Director, LifeSci Advisors, LLC | 212-915-2568 |